Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Precipio, Seq2Know, Stratify Genomics

Precipio HemeScreen

Precipio has commercially launched HemeScreen, a test for mutations in hematologic cancers. The test measures for mutations in the CALR, JAK2, and MPL genes, as well as in exon 12 of JAK2, all of which are critically important to developing a clinical roadmap for the patient, Precipio said. The company will offer the assay through its CLIA laboratory in New Haven, Connecticut, and will also offer a set of RUO reagents to other reference labs to perform the test in their CLIA laboratories.


Seq2Know Celiac Disease Testing

Seq2Know is offering testing for celiac disease. The firm's test includes sequencing of the DQA1 and DQB1 genes that have been associated with celiac disease. All tests will be ordered directly from Seq2Know.com and will be reviewed by PWNHealth to ensure the appropriateness of the test, the company said.


Stratify Genomics Prompt Prostate Cancer Test

Stratify Genomics has launched Prompt, its new lab-developed test to track a man's genetic predisposition to prostate cancer. According to the firm, Prompt incorporates genetic information from several prostate cancer-risk associated SNPs. Using population-based analyses, the test reports how many men out of 100 with a given genetic score would go on to develop prostate cancer. Clinicians can perform the test with a cheek swab sample to help men know their individual risk and potentially identify high-risk individuals.


For more new products and services, please visit the New Products page on our website.

Filed under

The Scan

For STEM Students to Stay

New policy changes will make it easier for international STEM students to stay in the US after graduation, the Wall Street Journal reports.

To Inform or Not, To Know or Not

The New York Times writes that some genetic biobanks may re-contact donors if they spot something troublesome, but it notes that not all donors want that information.

Rapid Test Studies

Researchers are examining why rapid tests may be less effective at detecting the Omicron variant and how to improve them, NPR says.

PLOS Papers on SARS-CoV-2 Diversity in Delaware, Metastatic Breast Cancer, Adiposity GWAS

In PLOS this week: genomic analysis of SARS-CoV-2 isolates from Delaware, gene expression and protein-protein interaction patterns in metastatic breast cancer, and more.